<DOC>
	<DOCNO>NCT00462943</DOCNO>
	<brief_summary>A Phase II open-label trial subcutaneous HHT ( omacetaxine mepesuccinate ) treatment patient resistant intolerant Tyrosine Kinase Inhibitors .</brief_summary>
	<brief_title>Open Label Study Subcutaneous Homoharringtonine ( Omacetaxine Mepesuccinate ) Patients With Advanced CML</brief_title>
	<detailed_description>This open label , multicenter study subcutaneous HHT ( omacetaxine mepesuccinate ) therapy patient chronic myeloid leukemia ( CML ) chronic , accelerate , blast phase fail intolerant tyrosine kinase inhibitor therapy . Patients treated induction course cycle consist subcutaneous ( SC ) HHT 1.25 mg/mÂ² twice daily 14 consecutive day every 28 day . Patients evaluate every 7 day complete blood platelet count undergoing induction therapy ; number consecutive dos HHT interval subsequent cycle may adjust , clinically indicate , accord guideline provide treatment plan .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<criteria>Male female patient , age 18 year old Philadelphia chromosome ( Ph ) positive chronic myelogenous leukemia either chronic , accelerate , blast phase Patients either fail , demonstrate intolerance , combination prior failure intolerance , prior treatment least two tyrosine kinase inhibitor ( TKI 's ) . Failure TKI treatment may either primary ( never achieve response ) secondary resistance ( loss response ) . Acceptable Renal Liver Function Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Sexually active patient partner must use effective double barrier method contraception New York Heart Association classification ( NYHA ) class III IV heart disease , active ischemia uncontrolled cardiac condition Myocardial infarction previous 12 week . Other concurrent illness would preclude study conduct assessment uncontrolled active infection , positive HIV positive HTLV I/II status , whether treatment . Pregnant lactating . Any medical psychiatric condition , may compromise ability give write informed consent comply study protocol . Lymphoid Ph+ blast crisis Patient enrol another clinical investigation within 30 day enrollment receive another investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>CML</keyword>
	<keyword>HHT</keyword>
	<keyword>Homoharringtonine</keyword>
	<keyword>Omacetaxine</keyword>
</DOC>